3'-hydroxybenanomicin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-hydroxybenanomicin A: structure given in first source; derived from PRM FA-2 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6918233
CHEMBL ID	4757176
MeSH ID	M0208387

Synonyms (14)

Synonym
d-serine, n-((5-((6-deoxy-3-o-beta-d-xylopyranosyl-beta-d-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)-, (5s-trans)-
bms 181184
bms-181184
139272-69-8
2-[[(5s)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxypropanoic acid
(2r)-2-[[(5s,6s)-5-[(2s,3r,4s,5s,6r)-3,5-dihydroxy-6-methyl-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxypropanoic acid
3'-hydroxybenanomicin a
unii-3bae3pzn9p
3bae3pzn9p ,
pradimicin x
d-serine, n-(((5s,6s)-5-((6-deoxy-3-o-.beta.-d-xylopyranosyl-.beta.-d-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)-
bmy-28960
d-serine, n-((5-((6-deoxy-3-o-.beta.-d-xylopyranosyl-.beta.-d-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)-, (5s-trans)-
CHEMBL4757176

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" Although treatment at all dosing regimens of BMS 181184 resulted in significant reductions in fungal tissue burden compared to untreated controls, equivalence to amphotericin B occurred only at the higher dosage level."	( Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Al-Mohsen, I; Bacher, J; Feuerstein, E; Giri, N; Gonzalez, CE; Groll, AH; Piscitelli, S; Sein, T; Shetty, D; Walsh, TJ, 1998)	0.3
" Across the investigated dosage range, BMS 181184 demonstrated nonlinear, dose-dependent kinetics with enhanced clearance, reciprocal shortening of elimination half-life, and an apparently expanding volume of distribution with increasing dosage."	( Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits. Bacher, J; Callender, D; Giri, N; Gonzalez, CE; Groll, AH; Petraitiene, R; Petraitis, V; Piscitelli, S; Sein, T; Walsh, TJ, 1998)	0.3

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID1717665	Antifungal activity against Candida albicans infected in mouse assessed as protection against fungus-induced lethal infection	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	10 (90.91)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (9.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.84 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (9.09%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.68	3	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	2	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
pradimicin fa 2 pradimicin FA 2: structure given in first source; des-N-methyl analog of pradimicin FA-1; isolated from Actinomadura hibisca	1.99	1
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	3.35	1	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
nikkomycin nikkomycin Z : A uridine-based nucleoside-peptide antibiotic which inhibits fungal chitin biosynthesis by inhibiting chitin synthase.	3.35	1	nikkomycin	antifungal agent
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	3.35	1	antibiotic antifungal drug; echinocandin	antiinfective agent
cancidas [no description available]	3.35	1
n,n-dimethylpradimicin fa-2 N,N-dimethylpradimicin FA-2: pradimicin A derivative; structure given in first source	3.35	1
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	4.2	5	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pradimicin a pradimicin A: from actinomycete strain No. P157-2; has inhibitory effect against HIV in vitro; structure given in first source. pradimicin A : A member of the class of pradimicins that is isolated from the cultured broth of Actinomadura hibisca No. P157-2 (ATCC 53557).	3.53	2	aromatic ether; carboxylic acid; disaccharide derivative; L-alanine derivative; p-quinones; polyphenol; pradimicin; secondary alcohol
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	3.35	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
n(3)-(4-methoxyfumaroyl)-2,3-diaminopropionic acid N(3)-(4-methoxyfumaroyl)-2,3-diaminopropionic acid: inhibits glucosamine synthetase in E coli; structure given in first source; RN given refers to (S-(E)-isomer). N(3)-(4-methoxyfumaroyl)-2,3-diaminopropionic acid : A monocarboxylic acid amide obtained by the formal condensation of the terminal amino group of 3-amino-L-alanine with the carboxy group of (2E)-4-methoxy-4-oxobut-2-enoic acid.	3.35	1	enoate ester; methyl ester; monocarboxylic acid amide	metabolite
yw 3548 YW 3548: inhibits glycosylphosphatidylinositol synthesis; structure in first source. YW3548 : A terpene lactone that is obtained from Codinea simplex and acts as an inhibitor of glycerophosphoinositol biosynthesis.	3.35	1	olefinic compound; terpene lactone; tertiary alcohol	fungal metabolite; glycerophosphoinositol synthesis inhibitor
3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine APX001A: has antifungal activity; structure in first source	3.35	1
enfumafungin enfumafungin: from endophytic Hormonema species; structure in first source. enfumafungin : A triterpene glycoside and hemiacetal isolated from a fermentation of Hormonema sp. and which specifically inhibits glucan synthesis in fungal cells.	3.35	1	lactol; monosaccharide derivative; triterpenoid saponin	antifungal agent

Condition	Relationship Strength	Studies
Fungal Diseases [description not available]	3.17	1
Mycoses Diseases caused by FUNGI.	3.17	1
Candida Infection [description not available]	2.9	4
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.9	4
C gattii Infection [description not available]	2.39	2
Fungemia The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.	1.99	1
Blastomycosis, North American [description not available]	1.99	1
Blastomycosis A fungal infection that may appear in two forms: 1, a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2, chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung.	1.99	1
Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS.	2.39	2
Aspergillus Infection [description not available]	2.39	2
Fungal Lung Diseases [description not available]	1.99	1
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	2.39	2

chemdatabank.com